Further studies are also needed to focus on the involvement of the PI3K/AKT pathway in E2F1/miR-375/SESN3-mediated ESCC progression with PI3K/AKT inhibitors. This evidence concerns the gene SESN3 and esophageal squamous cell carcinoma.